WO2008120472A1 - 高脂血症の予防及び/又は治療剤 - Google Patents
高脂血症の予防及び/又は治療剤 Download PDFInfo
- Publication number
- WO2008120472A1 WO2008120472A1 PCT/JP2008/000788 JP2008000788W WO2008120472A1 WO 2008120472 A1 WO2008120472 A1 WO 2008120472A1 JP 2008000788 W JP2008000788 W JP 2008000788W WO 2008120472 A1 WO2008120472 A1 WO 2008120472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- prophylactic
- hyperlipemia
- disclosed
- blood
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES08720655T ES2380752T3 (es) | 2007-03-29 | 2008-03-28 | Agente profiláctico y/o terapéutico para hiperlipidemia |
KR1020097018191A KR101420319B1 (ko) | 2007-03-29 | 2008-03-28 | 고지혈증 예방 및/또는 치료제 |
CN2008800033811A CN101627021B (zh) | 2007-03-29 | 2008-03-28 | 高脂血症的预防和/或治疗剂 |
EP08720655A EP2141155B1 (en) | 2007-03-29 | 2008-03-28 | Prophylactic and/or therapeutic agent for hyperlipidemia |
AT08720655T ATE549323T1 (de) | 2007-03-29 | 2008-03-28 | Prophylaktisches und/oder therapeutisches mittel gegen hyperlipidemie |
CA2680407A CA2680407C (en) | 2007-03-29 | 2008-03-28 | Prophylactic and/or therapeutic agent for hyperlipidemia |
US12/593,356 US8426455B2 (en) | 2007-03-29 | 2008-03-28 | Prophylactic and/or therapeutic agent for hyperlipidemia |
JP2009507415A JP5275975B2 (ja) | 2007-03-29 | 2008-03-28 | 高脂血症の予防及び/又は治療剤 |
HK10104519.2A HK1138277A1 (en) | 2007-03-29 | 2010-05-10 | Prophylactic and/or therapeutic agent for hyperlipemia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007087081 | 2007-03-29 | ||
JP2007-087081 | 2007-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008120472A1 true WO2008120472A1 (ja) | 2008-10-09 |
Family
ID=39808058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/000788 WO2008120472A1 (ja) | 2007-03-29 | 2008-03-28 | 高脂血症の予防及び/又は治療剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8426455B2 (ja) |
EP (2) | EP2433932A1 (ja) |
JP (1) | JP5275975B2 (ja) |
KR (1) | KR101420319B1 (ja) |
CN (1) | CN101627021B (ja) |
AT (1) | ATE549323T1 (ja) |
CA (1) | CA2680407C (ja) |
ES (1) | ES2380752T3 (ja) |
HK (1) | HK1138277A1 (ja) |
PT (1) | PT2141155E (ja) |
TW (1) | TWI407955B (ja) |
WO (1) | WO2008120472A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011037223A1 (ja) * | 2009-09-28 | 2011-03-31 | 興和株式会社 | 内臓脂肪重量の低下剤 |
WO2014050134A1 (ja) * | 2012-09-27 | 2014-04-03 | 興和株式会社 | 脂質異常症治療剤 |
WO2015030033A1 (ja) * | 2013-08-28 | 2015-03-05 | 興和株式会社 | 脂質異常症治療剤 |
JP2019011325A (ja) * | 2017-06-30 | 2019-01-24 | 興和株式会社 | 医薬組成物 |
JPWO2019216313A1 (ja) * | 2018-05-08 | 2021-05-13 | 国立大学法人 岡山大学 | 心血管疾患に有用な医薬 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102977085B (zh) * | 2011-10-27 | 2015-07-29 | 四川大学 | 2-芳基-苯并[d]噁唑、2-芳基-苯并[d]噻唑衍生物及其制备方法和用途 |
PT3275438T (pt) | 2016-07-29 | 2021-01-25 | Kowa Co | Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual |
EP3646865A4 (en) * | 2017-06-30 | 2021-03-17 | Kowa Company, Ltd. | MEDICINE |
EP3646866A4 (en) * | 2017-06-30 | 2021-03-24 | Kowa Company, Ltd. | PHARMACEUTICAL PREPARATION |
CN111741753A (zh) * | 2017-12-21 | 2020-10-02 | 兴和株式会社 | 治疗高甘油三酯血症的方法 |
US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
EP3903780A4 (en) * | 2018-12-27 | 2023-01-18 | Kowa Company, Ltd. | MEDICINAL PRODUCT |
KR102289381B1 (ko) | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01279866A (ja) | 1987-08-20 | 1989-11-10 | Nissan Chem Ind Ltd | キノリン系メバロノラクトン類 |
US6511985B1 (en) | 1998-12-18 | 2003-01-28 | Bayer Aktiengesellschaft | Combination of cerivastatin and fibrates |
WO2003013608A1 (en) | 2001-08-07 | 2003-02-20 | Galephar M/F | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR |
DE10200138A1 (de) | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
WO2003088962A1 (en) | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
WO2005023777A1 (ja) | 2003-09-03 | 2005-03-17 | Kowa Co., Ltd. | Ppar活性化化合物及びこれを含有する医薬組成物 |
WO2006090756A1 (ja) | 2005-02-25 | 2006-08-31 | Kyorin Pharmaceutical Co., Ltd. | 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
KR20020005662A (ko) | 1999-04-09 | 2002-01-17 | 기따자또 이찌로 | 질소함유 복소환화합물 및 벤즈아미드화합물 및 그 것을함유해서 되는 의약 |
CA2555316A1 (en) | 2004-02-09 | 2005-08-18 | Aska Pharmaceutical Co., Ltd. | Combined pharmaceutical composition |
PL1852426T3 (pl) * | 2005-02-23 | 2014-04-30 | Kowa Co | Sposób wytwarzania optycznie czynnego związku aktywującego PPAR oraz związku pośredniego |
AR054368A1 (es) | 2005-06-01 | 2007-06-20 | Takeda Pharmaceutical | Metodo para tratar hiperlipidemia |
-
2008
- 2008-03-20 TW TW097109834A patent/TWI407955B/zh active
- 2008-03-28 CA CA2680407A patent/CA2680407C/en not_active Expired - Fee Related
- 2008-03-28 EP EP11195053A patent/EP2433932A1/en not_active Withdrawn
- 2008-03-28 US US12/593,356 patent/US8426455B2/en active Active
- 2008-03-28 JP JP2009507415A patent/JP5275975B2/ja active Active
- 2008-03-28 ES ES08720655T patent/ES2380752T3/es active Active
- 2008-03-28 PT PT08720655T patent/PT2141155E/pt unknown
- 2008-03-28 EP EP08720655A patent/EP2141155B1/en active Active
- 2008-03-28 WO PCT/JP2008/000788 patent/WO2008120472A1/ja active Application Filing
- 2008-03-28 AT AT08720655T patent/ATE549323T1/de active
- 2008-03-28 CN CN2008800033811A patent/CN101627021B/zh active Active
- 2008-03-28 KR KR1020097018191A patent/KR101420319B1/ko active IP Right Grant
-
2010
- 2010-05-10 HK HK10104519.2A patent/HK1138277A1/xx unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01279866A (ja) | 1987-08-20 | 1989-11-10 | Nissan Chem Ind Ltd | キノリン系メバロノラクトン類 |
US5856336A (en) | 1987-08-20 | 1999-01-05 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones |
US6511985B1 (en) | 1998-12-18 | 2003-01-28 | Bayer Aktiengesellschaft | Combination of cerivastatin and fibrates |
WO2003013608A1 (en) | 2001-08-07 | 2003-02-20 | Galephar M/F | ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINAITION OF PPARα AND A HMG-COA REDUCTASE INHIBITOR |
DE10200138A1 (de) | 2002-01-04 | 2003-07-17 | Karl Winkler | Kombination von einem PPAR-Agonisten mit PPAR-alpha Aktivität mit einem Induktor des LDL-Rezeptors |
WO2003088962A1 (en) | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
WO2005023777A1 (ja) | 2003-09-03 | 2005-03-17 | Kowa Co., Ltd. | Ppar活性化化合物及びこれを含有する医薬組成物 |
WO2006090756A1 (ja) | 2005-02-25 | 2006-08-31 | Kyorin Pharmaceutical Co., Ltd. | 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用 |
Non-Patent Citations (14)
Title |
---|
ATHEROSCLEROSIS, vol. 124, 1996, pages 103 - 117 |
ATHEROSCLEROSIS, vol. 29, 1978, pages 269 - 275 |
ATHEROSCLEROSIS, vol. 74, 1988, pages 15 - 21 |
BIOCHIM. BIOPHYS. ACTA, vol. 1254, 1995, pages 7 - 12 |
DIABETES CARE, vol. 25, 2002, pages 1198 - 1202 |
INOUE I. ET AL.: "Fibrate and Statin Synergistically Increase the Transcriptional Activities of PPARgamma/RXRalpha and Decrease the Transactivation of NFkappaB", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 290, no. 1, 2002, pages 131 - 139, XP002996645 * |
J. CLIN. THERAP. MED., vol. 17, 2001, pages 857 - 883 |
J. LIPID. RES., vol. 39, 1998, pages 75 - 84 |
J. PHARMACOL. SCI., vol. 103, no. 1, 2007, pages 244P |
JOHNSON T.E. ET AL.: "Statins and PPARgamma agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 208, no. 3, 2005, pages 210 - 221, XP003006969 * |
TANAKA T. ET AL.: "Koshiketsusho Gappei 2-gata Tonyobyo Kanja ni Taisuru Fenofibrate no Chokiteki Yuyosei", PROGRESS IN MEDICINE, vol. 26, 2006, pages 1111 - 1116, XP008142108 * |
TERAMOTO T.: "Koshiketsusho Chiryo ni Okeru Fibrate-kei Yakuzai no Ichizuke - Daikibo Rinsho Shiken o Furikaette -", THERAPEUTIC RESEARCH, vol. 27, no. 10, 2006, pages 1979 - 1986, XP008116832 * |
USUI ET AL., LIPID RES., vol. 43, 2002, pages 805 - 814 |
YAMAZAKI H. ET AL.: "Shinki HMG-CoA Kangen Koso Sogaiyaku Pitavastatin (Livalo-jo) no Yakuri Oyobi Yakubutsu Dotaiteki Tokucho to Rinsho Koka", FOLIA PHARMACOLOGICA JAPONICA, vol. 123, 2004, pages 349 - 362, XP008116671 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5679458B2 (ja) * | 2009-09-28 | 2015-03-04 | 興和株式会社 | 内臓脂肪重量の低下剤 |
WO2011037223A1 (ja) * | 2009-09-28 | 2011-03-31 | 興和株式会社 | 内臓脂肪重量の低下剤 |
US10258609B2 (en) | 2012-09-27 | 2019-04-16 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
WO2014050134A1 (ja) * | 2012-09-27 | 2014-04-03 | 興和株式会社 | 脂質異常症治療剤 |
JPWO2014050134A1 (ja) * | 2012-09-27 | 2016-08-22 | 興和株式会社 | 脂質異常症治療剤 |
EA024873B1 (ru) * | 2012-09-27 | 2016-10-31 | Кова Компани, Лтд. | Терапевтическое средство при дислипидемии |
US9572798B2 (en) | 2012-09-27 | 2017-02-21 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
US11013722B2 (en) | 2012-09-27 | 2021-05-25 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
US9931321B2 (en) | 2012-09-27 | 2018-04-03 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
WO2015030033A1 (ja) * | 2013-08-28 | 2015-03-05 | 興和株式会社 | 脂質異常症治療剤 |
JP2018197273A (ja) * | 2013-08-28 | 2018-12-13 | 興和株式会社 | 脂質異常症治療剤 |
JPWO2015030033A1 (ja) * | 2013-08-28 | 2017-03-02 | 興和株式会社 | 脂質異常症治療剤 |
JP2019011325A (ja) * | 2017-06-30 | 2019-01-24 | 興和株式会社 | 医薬組成物 |
JPWO2019216313A1 (ja) * | 2018-05-08 | 2021-05-13 | 国立大学法人 岡山大学 | 心血管疾患に有用な医薬 |
JP7356968B2 (ja) | 2018-05-08 | 2023-10-05 | 国立大学法人 岡山大学 | 心血管疾患に有用な医薬 |
Also Published As
Publication number | Publication date |
---|---|
EP2141155A1 (en) | 2010-01-06 |
CA2680407C (en) | 2015-04-21 |
US20100069433A1 (en) | 2010-03-18 |
EP2141155A4 (en) | 2010-05-19 |
TW200838510A (en) | 2008-10-01 |
ATE549323T1 (de) | 2012-03-15 |
CA2680407A1 (en) | 2008-10-09 |
CN101627021A (zh) | 2010-01-13 |
EP2141155B1 (en) | 2012-03-14 |
EP2433932A1 (en) | 2012-03-28 |
KR101420319B1 (ko) | 2014-07-16 |
CN101627021B (zh) | 2012-11-28 |
TWI407955B (zh) | 2013-09-11 |
JP5275975B2 (ja) | 2013-08-28 |
KR20090129994A (ko) | 2009-12-17 |
US8426455B2 (en) | 2013-04-23 |
HK1138277A1 (en) | 2010-08-20 |
JPWO2008120472A1 (ja) | 2010-07-15 |
PT2141155E (pt) | 2012-05-23 |
ES2380752T3 (es) | 2012-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008120472A1 (ja) | 高脂血症の予防及び/又は治療剤 | |
WO2007056771A3 (en) | Compounds for the treatment of metabolic disorders | |
WO2008102749A1 (ja) | 複素環化合物 | |
WO2009051244A1 (ja) | 複素環化合物 | |
WO2008093639A1 (ja) | ピラゾール化合物 | |
WO2007118185A3 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
WO2006112549A8 (ja) | 縮合複素環化合物 | |
WO2007095601A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
WO2002100341A3 (en) | Compounds for the treatment of metabolic disorders | |
WO2008011453A3 (en) | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | |
WO2007125547A3 (en) | Novel process for statins and its pharmaceutically acceptable salts thereof | |
WO2008142859A1 (ja) | 新規なスピロオキシインドール化合物及びこれを含有する医薬 | |
MX2010009736A (es) | Compuesto heterociclico. | |
GEP20105033B (en) | Therapeutic agent for diabetes | |
WO2009051670A3 (en) | Oxylipin compounds for the treatment of ophthalmic conditions | |
WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
WO2007109354A3 (en) | Peptide-peptidase inhibitor conjugates and methods of using same | |
WO2007127688A3 (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
WO2010093849A3 (en) | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | |
WO2007145835A3 (en) | Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity | |
WO2006053043A3 (en) | Methods of treating diabetes mellitus | |
WO2006074244A3 (en) | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | |
IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
WO2008005651A3 (en) | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis | |
WO2004041165A3 (en) | Compounds for the treatment of metabolic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880003381.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08720655 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097018191 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008720655 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2680407 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009507415 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12593356 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |